Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

PURPOSE: To summarise post-licensure safety surveillance over more than 4 years of routine use of the human papillomavirus-16/18-AS04-adjuvanted vaccine (HPV-16/18 vaccine: Cervarix®, GlaxoSmithKline, Belgium). METHODS: We describe global post-licensure passive surveillance data based on routine pha...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiol Drug Saf
Main Authors: Angelo, Maria-Genalin, Zima, Julia, Tavares Da Silva, Fernanda, Baril, Laurence, Arellano, Felix
Format: Artigo
Language:Inglês
Published: BlackWell Publishing Ltd 2014
Subjects:
Reviews
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4265196/
https://ncbi.nlm.nih.gov/pubmed/24644078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.3593
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items